ATE320502T1 - Für eine glutamat-dekarboxylase-aktivität kodierende rekombinierende viren - Google Patents
Für eine glutamat-dekarboxylase-aktivität kodierende rekombinierende virenInfo
- Publication number
- ATE320502T1 ATE320502T1 AT95914389T AT95914389T ATE320502T1 AT E320502 T1 ATE320502 T1 AT E320502T1 AT 95914389 T AT95914389 T AT 95914389T AT 95914389 T AT95914389 T AT 95914389T AT E320502 T1 ATE320502 T1 AT E320502T1
- Authority
- AT
- Austria
- Prior art keywords
- virus
- glutamate decarboxylase
- recombining
- contg
- decarboxylase activity
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 5
- 102000008214 Glutamate decarboxylase Human genes 0.000 title abstract 3
- 108091022930 Glutamate decarboxylase Proteins 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 1
- 108091092584 GDNA Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 210000002744 extracellular matrix Anatomy 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9403411A FR2717823B1 (fr) | 1994-03-23 | 1994-03-23 | Virus recombinants, préparation et utilisation en thérapie génique. |
FR9413487A FR2726575B1 (fr) | 1994-11-09 | 1994-11-09 | Virus recombinants, preparation et utilisation en therapie genique |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE320502T1 true ATE320502T1 (de) | 2006-04-15 |
Family
ID=26231035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95914389T ATE320502T1 (de) | 1994-03-23 | 1995-03-21 | Für eine glutamat-dekarboxylase-aktivität kodierende rekombinierende viren |
Country Status (13)
Country | Link |
---|---|
US (1) | US20020028212A1 (de) |
EP (2) | EP0752003B1 (de) |
JP (1) | JPH09511394A (de) |
KR (1) | KR100403893B1 (de) |
AT (1) | ATE320502T1 (de) |
AU (1) | AU2140695A (de) |
CA (1) | CA2184297C (de) |
DE (1) | DE69534873T2 (de) |
FI (1) | FI963755A (de) |
IL (1) | IL113052A0 (de) |
MX (1) | MX9604026A (de) |
NO (1) | NO963806D0 (de) |
WO (1) | WO1995025805A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001213773A (ja) * | 2000-01-31 | 2001-08-07 | Yaegaki Hakko Giken Kk | 高血圧および糖尿病改善剤とγ−アミノ酪酸の製造方法 |
AU6808001A (en) | 2000-05-23 | 2001-12-03 | Neurologix Inc | Glutamic acid decarboxylase (gad) based delivery systems |
US7695959B2 (en) * | 2000-05-23 | 2010-04-13 | Neurologix, Inc. | Glutamic acid decarboxylase (GAD) based delivery systems |
US20160136095A1 (en) * | 2014-11-18 | 2016-05-19 | PixarBio Corporation | Methods for treating epilepsy or seizure disorders |
WO2017123676A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8424757D0 (en) | 1984-10-01 | 1984-11-07 | Pasteur Institut | Retroviral vector |
FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
EP0228458B2 (de) | 1985-07-05 | 1997-10-22 | Whitehead Institute For Biomedical Research | Expression von fremdem genetischem material in epithelzellen |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
EP0289034B1 (de) | 1987-05-01 | 1996-11-27 | The General Hospital Corporation | Transkaryotische Einpflanzung |
AU3069189A (en) | 1988-02-05 | 1989-08-25 | Trustees Of Columbia University In The City Of New York, The | Retroviral packaging cell lines and processes of using same |
WO1989007136A2 (en) | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
CA1339354C (en) | 1988-09-01 | 1997-08-26 | The Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5270452A (en) * | 1988-11-28 | 1993-12-14 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Pure glia maturation factor |
JPH04507041A (ja) | 1988-12-13 | 1992-12-10 | アメリカ合衆国 | 遺伝工学により修飾された内皮細胞およびその利用方法 |
JP2814529B2 (ja) * | 1989-03-16 | 1998-10-22 | 味の素株式会社 | 虚血性脳障害治療薬 |
US5585362A (en) * | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
CA2039921A1 (en) | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
ES2217250T3 (es) * | 1990-06-15 | 2004-11-01 | Scios Inc. | Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer. |
US6682906B1 (en) * | 1990-09-21 | 2004-01-27 | The Regents Of The University Of California | Cloned glutamic acid decarboxylase |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5189026A (en) * | 1991-06-07 | 1993-02-23 | Fractal Laboratories, Inc. | Treatment of human diseases involving dysregulation or dysfunction of the nervous system |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
FR2688514A1 (fr) * | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
EP0641330B1 (de) * | 1992-05-20 | 2001-10-17 | Northwestern University | Gaba und l-glutaminsaüre analoga zur behandlung der epilepsie |
JPH08501686A (ja) * | 1992-09-25 | 1996-02-27 | ローン−プーラン・ロレ・ソシエテ・アノニム | 中枢神経系、特に脳における細胞への外来遺伝子の転移のためのアデノウィルスベクター |
FR2702152B1 (fr) * | 1993-03-03 | 1995-05-24 | Inst Nat Sante Rech Med | Virus recombinants et leur utilisation en thérapie génique. |
FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
FR2707664B1 (fr) | 1993-07-13 | 1995-09-29 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
-
1995
- 1995-03-20 IL IL11305295A patent/IL113052A0/xx unknown
- 1995-03-21 US US08/704,583 patent/US20020028212A1/en not_active Abandoned
- 1995-03-21 AU AU21406/95A patent/AU2140695A/en not_active Abandoned
- 1995-03-21 JP JP7524435A patent/JPH09511394A/ja active Pending
- 1995-03-21 CA CA002184297A patent/CA2184297C/fr not_active Expired - Lifetime
- 1995-03-21 DE DE69534873T patent/DE69534873T2/de not_active Expired - Lifetime
- 1995-03-21 WO PCT/FR1995/000342 patent/WO1995025805A1/fr active Search and Examination
- 1995-03-21 AT AT95914389T patent/ATE320502T1/de not_active IP Right Cessation
- 1995-03-21 EP EP95914389A patent/EP0752003B1/de not_active Expired - Lifetime
- 1995-03-21 EP EP06004834A patent/EP1681354A3/de not_active Withdrawn
- 1995-03-21 KR KR1019960705265A patent/KR100403893B1/ko not_active IP Right Cessation
- 1995-03-21 MX MX9604026A patent/MX9604026A/es not_active IP Right Cessation
-
1996
- 1996-09-11 NO NO963806A patent/NO963806D0/no not_active Application Discontinuation
- 1996-09-20 FI FI963755A patent/FI963755A/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2184297C (fr) | 2009-09-29 |
US20020028212A1 (en) | 2002-03-07 |
IL113052A0 (en) | 1995-06-29 |
FI963755A0 (fi) | 1996-09-20 |
FI963755A (fi) | 1996-09-20 |
DE69534873T2 (de) | 2006-11-16 |
NO963806L (no) | 1996-09-11 |
DE69534873D1 (de) | 2006-05-11 |
NO963806D0 (no) | 1996-09-11 |
KR100403893B1 (ko) | 2004-02-19 |
KR970701785A (ko) | 1997-04-12 |
JPH09511394A (ja) | 1997-11-18 |
CA2184297A1 (fr) | 1995-09-28 |
MX9604026A (es) | 1997-09-30 |
EP1681354A2 (de) | 2006-07-19 |
EP0752003A1 (de) | 1997-01-08 |
AU2140695A (en) | 1995-10-09 |
EP0752003B1 (de) | 2006-03-15 |
EP1681354A3 (de) | 2010-08-11 |
WO1995025805A1 (fr) | 1995-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1394179T3 (da) | Fremgangsmåde til fremstilling af erythropoietin fri for animalske proteiner | |
ATE125869T1 (de) | Wachstumshormonfusionsproteine. | |
EP1005376A4 (de) | Methoden und zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie | |
DK374689D0 (da) | Dna-sekvenser, som koder for polypeptider med beta-1,3-glucanaseaktivitet | |
UA39161C2 (uk) | Рекомбінантний білок gm-csf для збільшення продукції гранулоцитів і макрофагів у пацієнтів, вектор і кднк, що його кодують | |
ATE284954T1 (de) | Hyaluronan synthase gen und seine verwendung | |
ATE92105T1 (de) | Expression von faktor-vii-aktivitaet in saeugetierzellen. | |
JPS6485084A (en) | Constellation of protein c | |
ATE318912T1 (de) | Polynukleotid kodierend für ein polypeptid mit heparanase-aktivität und dessen expression in transduzierten zellen | |
NO981044D0 (no) | Sirkulært DNA-molekyl med kondisjonell replikasjonsopprinnelse, dets fremstilling og anvendelse derav i genterapi | |
ATE93272T1 (de) | Expression von protein c. | |
AU682140B2 (en) | Multidrug resistance gene | |
AU637139B2 (en) | Gm-csf protein, its derivatives, the preparation of proteins of this type, and their use | |
DE69516416D1 (de) | Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen | |
ATE320502T1 (de) | Für eine glutamat-dekarboxylase-aktivität kodierende rekombinierende viren | |
DE60039677D1 (de) | Akt-3 nukleinsäure, polypeptide und deren verwendung | |
ATE127840T1 (de) | Charakterisierung und struktur der gene für protease a und protease b von streptomyces griseus. | |
NO891587D0 (no) | Fremgangsmaate for fremstilling av proteinholdige materiale ved dyrking av celler som inneholder rekombinante avipoxvirusvektorer. | |
EA200401390A1 (ru) | N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения | |
ES8605296A1 (es) | Procedimiento de producir factor viii-r humano | |
IL108584A0 (en) | Cloning of interferon - alpha beta binding protein | |
NO179453C (no) | Fremgangsmåte for fremstilling av terapeutisk aktivt amphiregulin, vertscelle som produserer proteinet, rekombinant vektor inneholdt i vertscellen, samt nukleotidsekvens som koder for proteiner med amphiregulinaktivitet | |
NO941982L (no) | Fremstilling av proteiner ved anvendelse av 7B2 protein | |
NO944878L (no) | Modifisert Kluyveromyces-gjær, dens fremstilling og anvendelse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |